Presage Biosciences Adds Board Member
The oncology company Presage Biosciences has appointed David Johnson to its board of directors. With 25 years’ experience Johnson joins Presage from the oncology focused company, Acerta Pharma, where he was CEO. He has held roles with increasing responsibilities within clinical development, medical affairs, pipeline development, and commercial at companies including Calistoga (acquired by Gilead), Gloucester (acquired by Celgene), Favrille, Millennium, Immunex (acquired by Amgen), and Hoffman La Roche.
You may also be interested in...
The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
New Chief Technology Officers named at Seres Therapeutics, ERYTech Pharma and Adicet Bio
Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.